Sphingolipids and the sphingosine kinase inhibitor, SKI II, induce BCL‐2‐independent apoptosis in human prostatic adenocarcinoma cells
The Prostate2007Vol. 67(15), pp. 1699–1717
Citations Over TimeTop 17% of 2007 papers
Michele LeRoux, Edmond J. Auzenne, Randall Evans, Numsen Hail, William H. Spohn, Sukhen C. Ghosh, D. Farquhar, Timothy McDonnell, Jim Klostergaard
Abstract
Thus, in contrast to the inhibitory effects of BCL-2 on apoptosis induced by various agents in tumor cells, SKI II and selected pro-apoptotic SLs appear atypical in their independence from such inhibition, and may have merits as new candidates for treatment of AI PC.
Related Papers
- → Sphingosine kinase-1 – a potential therapeutic target in cancer(2006)52 cited
- → Sphingolipid Signaling Pathways as Potential Therapeutic Targets in Gliomas(2007)36 cited
- → [3] Ceramide synthase(2000)39 cited
- → Sphingolipid metabolic changes during chiral C2-ceramides induced apoptosis in human leukemia cells(2001)6 cited
- → Role of Sphingolipids in Bacterial Infections(2020)1 cited